Skip to main content

Data & APIs
Events
Marketfy
Premarket Prep

+

Create your free account

Already have an account? Login

Name:

Email Address:

Password:

Leave blank:

By creating an account, you agree to the
Terms of Service and acknowledge our Privacy Policy.

+

Log in to your account

Email Address:

Password:

Forgot your password?

Don't have a Benzinga account? Create one

Contribute
Login
Join

News
- Earnings
- Guidance
- Dividends
- M&A
- Buybacks
- Legal
- Interviews
- Management
- Retail Sales
- Offerings
- IPOs
- Insider Trades
- Biotech/FDA
- Freight
- Tech
Markets
- Pre-Market
- After Hours
- Movers
- ETFs
- Forex
- Commodities
- Options
- Binary Options
- Bonds
- Futures
- Global Economics
- Previews
- Reviews
- Small-Cap
- Cryptocurrency
- Penny Stocks
Ratings
Ideas
Fintech
Investing
Crypto
Education
Premium

Market Overview

Tickers, Articles and Keywords:

Tickers

Articles

Keywords

Search by keyword...

googlecse

More From
Summary
Ideas
Twitter ($)
All News
Analyst Coverage
Analyst Ratings
News Coverage
News
General
Contracts
Dividend Summaries
Dividend Calendar
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Press Releases
Earnings
Earning Summaries
Earnings Calendar
Guidance Summaries

Protara Therapeutics, Inc. (TARA)

16.60 +1.70 (11.41%)

Analyst Ratings

Find Analyst Ratings for:

Date	Research Firm	Action	Current	PT
10/19/20	Cowen & Co.	Initiates Coverage On	Outperform	50.0
7/29/20	Guggenheim	Initiates Coverage On	Buy	50.0
1/22/20	Ladenburg Thalmann	Initiates Coverage On	Buy	45.0

Data powered by Benzinga Pro Calendars - Start your FREE TRIAL today!

Sign up to receive Benzinga's Daily Ratings Newsletter

Recent Ratings

TC (Downgrades)
GLNG (Downgrades)
LMNX (Downgrades)
NUAN (Downgrades)
BKNG (Upgrades)
AEE (Upgrades)
STNE (Downgrades)
IDA (Downgrades)
EH (Downgrades)
CADE (Downgrades)

News Coverage

Bitcoin Dominance Hits Two-Year Low As Crypto Market Prepares For 'Alt Season'
Mizuho Initiates Zscaler Stock At Buy: Here's Why
Jim Cramer On Amazon's Path To $5,700
Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline
Gordon Haskett's John Inch On Why General Electric Is 'Very Overvalued'
6 Reasons To Be Bullish On iHeartMedia Stock
Why This FedEx Analyst Sees Improving Express, Ground Prospects
What 29 Analyst Ratings Have To Say About Alphabet
Where Walt Disney Stands With Analysts
Analyst Ratings for CommScope Hldg Co

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
News Widget
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Privacy Policy / Do Not Sell My Personal Data
Disclaimer
Service Status
Sitemap

© 2021 Benzinga | All Rights Reserved